Intech Biopharm Ltd (6461)

Currency in TWD
19.15
-0.65(-3.28%)
Closed·

6461 Financial Summary

Key Ratios

P/E Ratio-7.63
Price/Book4.02
Debt / Equity208.36%
Return on Equity-41.87%
Dividend Yield0.00%
EBITDA-269.80M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of TWD (except for per share items)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
-0.64 / --
Revenue / Forecast
7.66M / --
EPS Revisions
Last 90 days

FAQ

What were Intech Biopharm's earnings for the latest quarter?

The Intech Biopharm EPS (TTM) is -2.78. Intech Biopharm reported sales of 7.66, net income of -88.35, and EPS of -0.64 for the latest quarter.

What was Intech Biopharm's net income for the latest quarter?

Intech Biopharm's net income for the latest quarter was -88.35.

How did Intech Biopharm's performance compare year-over-year in the latest quarter?

The company's revenue moved from 11.15 in the previous quarter to 7.66 in the latest quarter, and net income moved from -104.70 to -88.35 compared to the previous quarter.

What is Intech Biopharm's net profit margin on a TTM basis?

Intech Biopharm's trailing twelve months (TTM) net profit margin is -925.63%.

How does Intech Biopharm's debt to equity ratio compare to industry standards?

Intech Biopharm's total debt-to-equity ratio is 208.36%.

What is Intech Biopharm's return on investment on a TTM basis?

Intech Biopharm's trailing twelve months (TTM) return on investment (ROI) is -41.87%.

Did Intech Biopharm gain or lose cash last quarter?

In the latest quarter, Intech Biopharm's net change in cash was 8.54 million.

What were Intech Biopharm's total assets and liabilities in the latest quarter?

As of the latest quarter, Intech Biopharm reported total assets of 2,372.47 million and total liabilities of 446.11 million.

How has Intech Biopharm's total revenue grown this year?

Intech Biopharm's total revenue was 11.15 in the previous quarter and 7.66 in the latest quarter.

What is Intech Biopharm's gross margin on a TTM basis?

Intech Biopharm's trailing twelve months (TTM) gross margin is -505.17%.

What was Intech Biopharm's revenue per share for the latest quarter?

Intech Biopharm's revenue per share for the latest quarter was 23.13.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.